Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yondelis dosing schedules in advanced liposarcoma or leiomyosarcoma
NCT00060944Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2003
- Primary completion
- May 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of trabectedin in Liposarcoma and leiomyosarcoma (LMS) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Time to Progression at 5 years. Started May 2003; status: completed.
02
Drugs
trabectedin
03
Conditions
Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT00060944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060944.